BioWa Extends Licensing of Potelligent Technology To MedImmune

November 6, 2007
BioPharm International Editors

BioWa Inc., (Princeton, NJ) has entered into a second agreement with MedImmune to provide additional access to BioWa’s patented Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

BioWa Inc., (Princeton, NJ) has entered into a second agreement with MedImmune to provide additional access to BioWa’s patented Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants to MedImmune nonexclusive license rights to develop, manufacture, and market antibodies based on Potelligent technology for an undisclosed number of targets. In return, BioWa will receive certain fees and milestone payments from MedImmune during product development and royalties on marketed products using ADCC enhanced antibodies.

Potelligent technology is designed to improve the potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of antibody therapeutics. Potelligent technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that Potelligent technology significantly enhances ADCC activity of an antibody in vitro, thereby increasing the potential for improved activity in vivo.

BioWa release

Related Content:

News